Moreover, it normalized Aβ-induced τ phosphorylation in neuronal cells at 5 and 10 μM concentrations and DYRK1A-induced Aβ production in APP over-expressing cells (IC50 = 1.06 μM) emerging as a promising τ and amyloid-directed agent to alter the onset or progression of AD and other tauopathies [153]. This evidence concerns the gene APP and Alzheimer disease.